Tuoc Dao, MD
Surgical Oncology · Dallas, TXNPI 1295938462
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $500 of the $772 with a category attached, or 64.7%. Bard Peripheral Vascular, Inc. accounts for 64.7% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $516 and has fallen 89.1% since, to $56 in 2025. That places this record below the midpoint for surgical oncology clinicians in TX, where the typical reported total is $1,562.
Across 12 payments — averaging $64.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$500
- Bioptics, Inc.$102
- Merck$56
- Focal Therapeutics, Inc.$32
- Avanos Medical$28
- Boston Scientific$16
- plus $39 from 3 others
What the payments were for
- Speaking & faculty fees$50065%
- Food & beverage$27235%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bard Peripheral Vascular, Inc. | 1 | $500 |
| Bioptics, Inc. | 2 | $102 |
| Merck | 3 | $56 |
| Focal Therapeutics, Inc. | 1 | $32 |
| Avanos Medical | 1 | $28 |
| Boston Scientific | 1 | $16 |
| Tempus AI, Inc | 1 | $15 |
| Smith+Nephew | 1 | $12 |
| Tactile Systems Technology Inc | 1 | $12 |
How this compares
$772 in reported general payments places this provider in the 35th percentile of 191 surgical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tramadol Hcl | 59 | $298 |
| Doxycycline Monohydrate | 13 | $143 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Dallas
- Allison DipasqualeDallas$272K
- Adam YoppDallas$96K
- Peter BeitschDallas$62K
- Patricio PolancoDallas$61K
- William McNamaraDallas$16K
- Glen BalchDallas$11K
- Michael ChotiDallas$6K
- Deborah FarrDallas$4K
- David KangDallas$4K
- Merrick RossHouston$216K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.